The SREBP2-LDL receptor axis is already a well-established target for cholesterol-lowering therapeutics in cardiovascular disease, and PRDM16 is a very attractive target for obesity and T2D. This evidence concerns the gene SREBF2 and type 2 diabetes mellitus.